These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 29157617

  • 21. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
    Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S.
    Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
    [Abstract] [Full Text] [Related]

  • 22. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K.
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [Abstract] [Full Text] [Related]

  • 23. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R.
    Cureus; 2020 Jul 02; 12(7):e8967. PubMed ID: 32766009
    [Abstract] [Full Text] [Related]

  • 24. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K.
    J Korean Med Sci; 2010 Sep 02; 25(9):1364-7. PubMed ID: 20808682
    [Abstract] [Full Text] [Related]

  • 25. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC.
    Hematology Am Soc Hematol Educ Program; 2018 Nov 30; 2018(1):318-325. PubMed ID: 30504327
    [Abstract] [Full Text] [Related]

  • 26. Siltuximab for multicentric Castleman disease.
    Liu YC, Stone K, van Rhee F.
    Expert Rev Hematol; 2014 Oct 30; 7(5):545-57. PubMed ID: 25110138
    [Abstract] [Full Text] [Related]

  • 27. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3659-70. PubMed ID: 23659971
    [Abstract] [Full Text] [Related]

  • 28. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
    Plano F, Mancuso S, Camarda GM, Butera MG, Sucato G, Alecci G, Florena AM, Perrone S, Siragusa SM.
    Chemotherapy; 2024 Jul 01; 69(1):35-39. PubMed ID: 37634492
    [Abstract] [Full Text] [Related]

  • 29. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C, Boucheron A, Guillaume S, Koné-Paut I.
    Mol Cancer Ther; 2012 Aug 01; 11(8):1623-6. PubMed ID: 22638145
    [Abstract] [Full Text] [Related]

  • 30. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
    Intern Med; 2007 Aug 01; 46(11):771-4. PubMed ID: 17541233
    [Abstract] [Full Text] [Related]

  • 31. Siltuximab: first global approval.
    Markham A, Patel T.
    Drugs; 2014 Jul 01; 74(10):1147-52. PubMed ID: 24958337
    [Abstract] [Full Text] [Related]

  • 32. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
    Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M.
    Int J Hematol; 2009 Jul 01; 90(1):99-102. PubMed ID: 19554396
    [Abstract] [Full Text] [Related]

  • 33. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L, Bonfichi M, Ferrero S, Malipiero G, Nozza A, Argnani L, Zinzani PL.
    Hematol Oncol; 2018 Oct 01; 36(4):689-692. PubMed ID: 30074630
    [Abstract] [Full Text] [Related]

  • 34. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.
    Blood; 2018 Nov 15; 132(20):2115-2124. PubMed ID: 30181172
    [Abstract] [Full Text] [Related]

  • 35. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.
    Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, Tanaka K, Nakamura Y, Kinowaki K, Ohashi K, Fujii T, Igawa T, Sato Y, Ishii Y.
    BMC Nephrol; 2018 Oct 11; 19(1):263. PubMed ID: 30314457
    [Abstract] [Full Text] [Related]

  • 36. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC, Kurzrock R.
    Immunotherapy; 2016 Oct 11; 8(1):17-26. PubMed ID: 26634298
    [Abstract] [Full Text] [Related]

  • 37. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
    Milota T, Střížová Z, Sobotková M, Bartůňková J.
    Cas Lek Cesk; 2023 Oct 11; 162(2-3):106-111. PubMed ID: 37474295
    [Abstract] [Full Text] [Related]

  • 38. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA.
    BioDrugs; 2015 Dec 11; 29(6):399-406. PubMed ID: 26394632
    [Abstract] [Full Text] [Related]

  • 39. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.
    Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, Mikami Y, Hata H, Okuno Y, Mitsuya H, Nosaka K.
    Int J Hematol; 2016 Jun 11; 103(6):718-23. PubMed ID: 26980221
    [Abstract] [Full Text] [Related]

  • 40. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N, Morishita Y, Oh I, Saito O, Takemoto F, Muto S, Kusano E.
    Intern Med; 2012 Jun 11; 51(11):1375-8. PubMed ID: 22687845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.